Day One Biopharma Q2 OJEMDA revenue $33.6M (+310% YoY), guides FY2025 $140-150M

Day One Biopharmaceuticals, Inc.

2025-Q2 EPS reported -$0.64 revenue$64,669,000

OJEMDA net product revenue $33.6M in Q2 2025, up 310% YoY and 10% QoQ; prescriptions exceeded 1,000.
Full-year 2025 OJEMDA net product revenue guidance set at $140-150M.
Net loss of $30.3M in Q2 2025 ($4.4M loss in Q2 2024 included $108M priority voucher gain).
Cash, cash equivalents and short-term investments $453.1M as of June 30, 2025.
Pipeline: DAY301 PTK7-ADC enrolling Phase 1a; FIREFLY-2 enrollment on track for H1 2026.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.